Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophreniform Disorder
DECIFER: Depression and Citalopram In First Episode Recovery
This study seeks to examine the effectiveness of citalopram added to treatment with any oral or injectable second-generation antipsychotic plus standardized psychoeducation in first episode schizophrenia patients.
- Trial name
- DECIFER (NCT01041274)
- Testing
- Citalopram, Psychoeducation, Cognitive Behavioral Therapy (CBT)
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- NYU Langone Health
Schizophrenia, Psychosis
Aripiprazole Treatment of Prodromal Patients
We hypothesize that symptoms will improve in patients who meet diagnostic criteria for the schizophrenia prodrome when they are prescribed aripiprazole.
- Trial name
- NCT00237874
- Testing
- Aripiprazole
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Yale University
Schizophrenia, Bipolar I Disorder
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)
This study is an open label, sequential-group, two site, multiple dose escalating study of sublingual administered asenapine in a pediatric population with schizophrenia or bipolar I disorder; in one study cohort (3a)…
- Trial name
- NCT01206517
- Testing
- Asenapine 2.5 mg, Asenapine 5 mg, Asenapine 10 mg
- Volunteers
- 30 people
- Sponsor
- Organon and Co
Auditory Hallucinations in Patients With Schizophrenic Disorders
High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in Schizophrenia : a Randomized Controlled Study
Background: Repetitive transcranial magnetic stimulation (rTMS) is a recent therapeutic which has demonstrated its efficacy in the treatment of auditory hallucinations in patients with schizophrenic disorders.
- Trial name
- TMS-Hz (NCT01022489)
- Testing
- Transcranial magnetic stimulation: rTMS
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Caen
Schizophrenia, Bipolar Disorder
Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study
For more severe and treatment-resistant cases in schizophrenia and bipolar disorder, electroconvulsive therapy (ECT) is often very effective.
- Trial name
- NCT03651674
- Testing
- ECT treatment, Drug treatment
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xidian University
Schizophrenia and Related Disorders, Bipolar Disorder
Exercise Therapy in Mental Disorders-study
The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder.
- Trial name
- NCT06313918
- Testing
- High intensity training (HIT)
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Haukeland University Hospital
Schizophrenia
Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia
Antipsychotic alone is limit to improve the overall outcome of schizophrenia and has a high discontinue rate.To solve these problems, we provide practical and available psychosocial intervention.
- Trial name
- ACPIOS (NCT00654576)
- Testing
- Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole, psychosocial intervention
- Where
- China
- Volunteers
- 1,400 people
- Sponsor
- Central South University
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophreniform Disorder, Schizoaffective Disorder
Open-label Ziprasidone Study for Psychosis Treatment in Adolescents
This open-label study will assess the medication Geodon® (Ziprasidone) in pediatric patients, aged 13-17, diagnosed with psychotic disorder.
- Conditions
- Schizophreniform Disorder, Schizoaffective Disorder, Psychosis, Depressive Disorder, Major
- Trial name
- NCT00421954
- Testing
- Ziprasidone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Mental Disorders, Severe
Measuring Development of Brain Responses to Vocal Sounds in Babies of Mums With Mental Illness
CAPRI-Voc examines the differences in how speech and environmental sounds are processed in the infant brain as they grow from 9 to 12 months.
- Trial name
- CAPRI-Voc (NCT04350294)
- Where
- United Kingdom
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Attention Deficit Hyperactivity Disorder, Schizophrenia
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
Magnetic Resonance Imaging (MRI) unlike X-rays and CT-scans does not use radiation to create a picture. MRI use as the name implies, magnetism to create pictures with excellent anatomical resolution.
- Conditions
- Attention Deficit Hyperactivity Disorder, Schizophrenia, Attention Deficit Disorder With Hyperactivity
- Trial name
- NCT00001246
- Where
- United States
- Volunteers
- 4,276 people
- Sponsor
- National Institute of Mental Health (NIMH)
Psychotic Disorders, Psychosis
Semantic and Syntactic Computerized Analysis of Free Speech
Subtle speech disorganization could be predictive of a transition to schizophrenia of ultra-high-risk patients. The aim of our longitudinal multicenter cohort study is to identify specific linguistic markers of the psychotic…
- Conditions
- Psychotic Disorders, Psychosis, Schizophrenia and Related Disorders, Schizophrenia Prodromal
- Trial name
- ASESID (NCT03525054)
- Where
- 3 sites in France
- Volunteers
- 215 people
- Sponsor
- University Hospital, Brest
Schizophrenia, Affective Disorders
Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness
The purpose of this research is to determine if Ziprasidone is safe and effective for use in children and adolescents with a psychotic illness, and to determine of Ziprasidone treatment leads to weight changes in children.
- Conditions
- Schizophrenia, Affective Disorders, Psychotic Disorder, Psychotic Mood Disorder
- Trial name
- NCT00199940
- Testing
- Ziprasidone
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Schizophrenia, Schizophreniform Disorder
Integrated Care in Psychotic Disorders With Severe Mental Illness
The study examine the effectiveness of an integrated care program including therapeutic assertive community treatment (ACT) for people with psychotic disorders fulfilling severe and persistent mental illness (SPMI, ACCESS-II…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Delusional Disorder
- Trial name
- ACCESS-II (NCT01888627)
- Testing
- Integrated care
- Where
- Germany
- Volunteers
- 400 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia, Psychotic Disorders
Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
This is a randomized pilot study of an intervention based on principles of Cognitive Behavioral Therapy (CBT). This intervention is the Health Dialogue Intervention (HDI) and will be compared to a traditional medical model of…
- Trial name
- NCT00980252
- Testing
- Cognitive Behavioral Therapy
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Illinois Chicago
Clinical High Risk for Psychosis (CHR)
French Validation of Schizophrenia Proneness Instrument- Child Youth
The clinical concept of a at risk mental state of developing psychosis is based on the identification of attenuated psychotic symptoms during the prodromal phase of psychoses (Schmidt et al., 2015).
- Trial name
- SPI-CY-Fr (NCT06649552)
- Testing
- Psychiatric and psychological diagnostic tests
- Where
- 3 sites in France
- Volunteers
- 52 people
- Sponsor
- Centre Psychothérapique de Nancy
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.